What did @peptidecentre actually say?
The creator claims that taking BPC-157 for "just a couple of weeks" produced more healing progress on serious injuries, including labrum tears, disc herniations, and hairline fractures, than "years of physical therapy, chiropractic care, massage therapy, acupuncture." They also describe improved motivation and gym performance. This is not a vague wellness claim. It is a specific, comparative medical assertion about structural tissue repair in a compressed timeframe, and it deserves scrutiny proportional to how bold it is.
Does the science back this up?
Animal data on BPC-157 is genuinely interesting. That much is true. But "interesting animal data" and "heals human labrum tears in two weeks" are separated by a very large gap that the creator simply jumps over.
BPC-157, a synthetic pentadecapeptide derived from a gastric protein, has shown pro-angiogenic and tendon-healing effects in rodent models. Sikiric et al. (2018, Current Pharmaceutical Design) documented accelerated tendon-to-bone healing in rats. Chang et al. (2011, Journal of Applied Physiology) found improved Achilles tendon recovery in animal subjects. These are real findings. The problem is that no completed, peer-reviewed randomized controlled trial in humans has validated these outcomes. The FDA has not approved BPC-157 for any indication. Labrum tears and disc herniations involve complex cartilaginous and fibrous structures. The idea that any peptide resolves these in two weeks, outperforming years of multimodal rehabilitation, has no human clinical evidence behind it.
What did they get wrong (or right)?
They got the enthusiasm right and the evidence wrong. BPC-157 does have a plausible biological mechanism. It appears to influence growth hormone receptor expression and nitric oxide pathways, which could support tissue repair. That is not nothing. But the creator conflates rodent pharmacology with human outcomes and layers a personal anecdote on top as if it constitutes proof.
Calling labrum tears and disc herniations conditions that resolved in weeks is particularly problematic. Labrum repairs, surgically or otherwise, typically require months of rehabilitation. A self-reported improvement in pain or mobility is not the same as structural tissue healing, and the creator does not distinguish between the two. That conflation is misleading to viewers who may be managing serious orthopedic injuries and looking for alternatives to surgery or extended rehab programs.
The framing of a "trial" with "spots disappearing fast" is also worth naming plainly: this is a sales mechanism, not a clinical trial. Real trials have IRB approval, control groups, and outcome measures. This has a TikTok caption.
What should you actually know?
BPC-157 is not approved by the FDA for human use and is classified as a research compound. In 2022, the FDA moved to restrict its use in compounded preparations, citing insufficient safety and efficacy data in humans. That regulatory position exists for a reason.
If you are managing a labrum tear, disc herniation, or fracture, the evidence base for physical therapy, particularly for rotator cuff and hip labrum pathology, is substantially stronger than anything currently available for BPC-157 in humans. Kuhn et al. (2013, Journal of Bone and Joint Surgery) found non-operative management effective for a meaningful subset of rotator cuff tears. That does not make PT perfect, but it has human data behind it.
Peptide research is a legitimate and evolving field. Some compounds in this category will probably prove clinically useful. BPC-157 might be one of them, eventually. But "might be useful someday" is not the same as "healed my labrum in two weeks," and anyone selling you the latter while citing the former is doing you a disservice.